Zogenix Inc (ZGNX) 1.15 $ZGNX
The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities 2014-19: Egalet 002 to Take Over from Oxycontin and Oxycodone
M2 - Mon Dec 08, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/t568bs/the_us_chronic) has announced the addition of the "The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-19)" report to their offering. The report titled The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019) provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating. The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market. Company Coverage - Zogenix Inc. - Egalet Corporation - NektarTheropeutics Key Topics Covered: 1. Executive summary 2. Introduction: Chronic Pain 3. The US Chronic Pain Therapy Market 4. The US Chronic Pain Therapy Market: Segment Analysis 5. The US Chronic Pain Therapy: Market Share Analysis 6. Growth Drivers and Challenges:The US Chronic Pain Therapy Market 8. Competitive Landscape:The US Chronic Pain Therapy Market 9. Company Profiles:The US Chronic Pain Therapy Market For more information visit http://www.researchandmarkets.com/research/t5...us_chronic
EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02)
Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Wed Dec 03, 4:41PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr, President, and Ann Rhoads, Chief Financial Officer, will present at the Oppenheimer 25 Annual Healthcare Conference in New York, NY on December 10, 2014.
ZGNX: 1.15 (-0.02)
United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com
PRWeb - Tue Dec 02, 2:55AM CST
The report titled "The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)" provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.
EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02)
Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
GlobeNewswire - Mon Dec 01, 7:30AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the publication of a long-term Phase 3 open-label study, which showed that Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, were generally safe, well-tolerated and effective in treating chronic pain for up to one year. The complete findings were published in the November 2014 issue of the Journal of Pain Research (available online here).
ZGNX: 1.15 (-0.02)
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST
MNK: 94.72 (-0.36), EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02), PFE: 30.95 (-0.70), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), ALKS: 54.41 (-1.22), ACUR: 0.47 (-0.05)
Zogenix to Participate in Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 3:30PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Stifel 2014 Healthcare Conference in New York, NY on November 18, 2014.
ZGNX: 1.15 (-0.02)
Zogenix's (ZGNX) CEO Roger Hawley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:01PM CST
ZGNX: 1.15 (-0.02)
Zogenix beats Street 3Q forecasts
Automated Insights - Thu Nov 06, 3:46PM CST
SAN DIEGO (AP) _ Zogenix Inc. (ZGNX) on Thursday reported a third-quarter loss of $12.8 million.
ZGNX: 1.15 (-0.02)
Zogenix Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:20PM CST
Conference Call and Webcast Today, November 6, at 4:30 p.m. ET
ZGNX: 1.15 (-0.02)
Zogenix beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:16PM CST
ZGNX: 1.15 (-0.02)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.15 (-0.02), PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), TTHI: 6.45 (+0.04), TEVA: 55.92 (-0.92), ITCI: 15.79 (-0.47), LLY: 69.55 (-2.06), OMER: 22.81 (+0.12)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.15 (-0.02), SHPG: 213.70 (-0.41), MRK: 57.72 (-1.62), PFE: 30.95 (-0.70), SNY: 45.16 (-1.05)
Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release Hydrocodone Products
GlobeNewswire - Fri Oct 31, 7:30AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has entered into an agreement with Purdue Pharma L.P. (Purdue) under which the two companies have exchanged waivers of regulatory exclusivity applicable to their respective single-entity, extended-release hydrocodone products. These waivers are applicable to current or pending New Drug Applications (NDAs) as well as successor products, including those with abuse-deterrent properties and associated labeling claims.
ZGNX: 1.15 (-0.02)
Zogenix Announces Conference Call and Webcast to Present Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 3:49PM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the third quarter ended September 30, 2014, after the market closes on Thursday November 6, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.
ZGNX: 1.15 (-0.02)
Zogenix Acquires U.K.-Based Brabant Pharma
GlobeNewswire - Mon Oct 27, 6:30AM CDT
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy
ZGNX: 1.15 (-0.02)
FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT
MNK: 94.72 (-0.36), EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02), PFE: 30.95 (-0.70), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), ALKS: 54.41 (-1.22), ACUR: 0.47 (-0.05)
Zogenix (ZGNX) Shows Strength: Stock Adds 11.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:39AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as the company shares rose over 11% on the day.
LCI: 43.58 (-0.46), ZGNX: 1.15 (-0.02), SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Oct 03, 8:19AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
LOJN: 2.51 (-0.08), JAKK: 6.77 (-0.10), AVNW: 1.44 (+0.02), ZGNX: 1.15 (-0.02), WGBS: 3.51 (-0.03), SPWH: 7.31 (-0.20)
Drugmaker submits harder-to-abuse Zohydro to FDA
By MATTHEW PERRONE - AP - Wed Oct 01, 1:33PM CDT
WASHINGTON (AP) — The maker of the much-debated painkiller Zohydro is seeking approval of a harder-to-abuse version of the drug which, if approved, could replace the currently marketed version of the pill by next spring.
ZGNX: 1.15 (-0.02)
Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for a modified formulation of Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, which has been designed to have abuse deterrent properties. The new capsule formulation contains additional inactive ingredients that are intended to make the product more difficult to abuse by injection and nasal insufflation. The Company anticipates a target action date on the supplement during the first quarter of 2015, and, if approved, a transition from the currently marketed product to this new formulation of Zohydro ER in the second quarter of 2015.
ZGNX: 1.15 (-0.02)
The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities 2014-19: Egalet 002 to Take Over from Oxycontin and Oxycodone
M2 - Mon Dec 08, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/t568bs/the_us_chronic) has announced the addition of the "The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-19)" report to their offering. The report titled The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019) provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating. The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market. Company Coverage - Zogenix Inc. - Egalet Corporation - NektarTheropeutics Key Topics Covered: 1. Executive summary 2. Introduction: Chronic Pain 3. The US Chronic Pain Therapy Market 4. The US Chronic Pain Therapy Market: Segment Analysis 5. The US Chronic Pain Therapy: Market Share Analysis 6. Growth Drivers and Challenges:The US Chronic Pain Therapy Market 8. Competitive Landscape:The US Chronic Pain Therapy Market 9. Company Profiles:The US Chronic Pain Therapy Market For more information visit http://www.researchandmarkets.com/research/t5...us_chronic
EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02)
Zogenix to Participate in Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Wed Dec 03, 4:41PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Stephen Farr, President, and Ann Rhoads, Chief Financial Officer, will present at the Oppenheimer 25 Annual Healthcare Conference in New York, NY on December 10, 2014.
ZGNX: 1.15 (-0.02)
United States Chronic Pain Industry 2014 Trends and 2019 Opportunities Now Available at MarketReportsOnline.com
PRWeb - Tue Dec 02, 2:55AM CST
The report titled "The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)" provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.
EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02)
Results of Long-Term, Open-Label Study Published in the Journal of Pain Research Demonstrate the Safety, Tolerability and Effectiveness of Zohydro(R) ER
GlobeNewswire - Mon Dec 01, 7:30AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced the publication of a long-term Phase 3 open-label study, which showed that Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, were generally safe, well-tolerated and effective in treating chronic pain for up to one year. The complete findings were published in the November 2014 issue of the Journal of Pain Research (available online here).
ZGNX: 1.15 (-0.02)
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST
MNK: 94.72 (-0.36), EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02), PFE: 30.95 (-0.70), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), ALKS: 54.41 (-1.22), ACUR: 0.47 (-0.05)
Zogenix to Participate in Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 3:30PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that Zogenix management will present at the Stifel 2014 Healthcare Conference in New York, NY on November 18, 2014.
ZGNX: 1.15 (-0.02)
Zogenix's (ZGNX) CEO Roger Hawley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:01PM CST
ZGNX: 1.15 (-0.02)
Zogenix beats Street 3Q forecasts
Automated Insights - Thu Nov 06, 3:46PM CST
SAN DIEGO (AP) _ Zogenix Inc. (ZGNX) on Thursday reported a third-quarter loss of $12.8 million.
ZGNX: 1.15 (-0.02)
Zogenix Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:20PM CST
Conference Call and Webcast Today, November 6, at 4:30 p.m. ET
ZGNX: 1.15 (-0.02)
Zogenix beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:16PM CST
ZGNX: 1.15 (-0.02)
Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.15 (-0.02), PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), TTHI: 6.45 (+0.04), TEVA: 55.92 (-0.92), ITCI: 15.79 (-0.47), LLY: 69.55 (-2.06), OMER: 22.81 (+0.12)
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
PR Newswire - Tue Nov 04, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), Sanofi (NYSE: SNY), Shire PLC (NASDAQ: SHPG), and Zogenix Inc. (NASDAQ: ZGNX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 03, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,366.24, down 0.14% and the NASDAQ Composite closed at 4,638.91, up 0.18%. The S&P 500 finished the session 0.01% lower at 2,017.81. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index gaining 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.15 (-0.02), SHPG: 213.70 (-0.41), MRK: 57.72 (-1.62), PFE: 30.95 (-0.70), SNY: 45.16 (-1.05)
Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release Hydrocodone Products
GlobeNewswire - Fri Oct 31, 7:30AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has entered into an agreement with Purdue Pharma L.P. (Purdue) under which the two companies have exchanged waivers of regulatory exclusivity applicable to their respective single-entity, extended-release hydrocodone products. These waivers are applicable to current or pending New Drug Applications (NDAs) as well as successor products, including those with abuse-deterrent properties and associated labeling claims.
ZGNX: 1.15 (-0.02)
Zogenix Announces Conference Call and Webcast to Present Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 3:49PM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the third quarter ended September 30, 2014, after the market closes on Thursday November 6, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.
ZGNX: 1.15 (-0.02)
Zogenix Acquires U.K.-Based Brabant Pharma
GlobeNewswire - Mon Oct 27, 6:30AM CDT
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy
ZGNX: 1.15 (-0.02)
FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT
MNK: 94.72 (-0.36), EGLT: 6.26 (+0.19), ZGNX: 1.15 (-0.02), PFE: 30.95 (-0.70), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), ALKS: 54.41 (-1.22), ACUR: 0.47 (-0.05)
Zogenix (ZGNX) Shows Strength: Stock Adds 11.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:39AM CDT
Zogenix, Inc. (ZGNX) was a big mover last session, as the company shares rose over 11% on the day.
LCI: 43.58 (-0.46), ZGNX: 1.15 (-0.02), SGNT: 27.85 (-0.65), HPTX: 21.89 (+0.02)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Oct 03, 8:19AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
LOJN: 2.51 (-0.08), JAKK: 6.77 (-0.10), AVNW: 1.44 (+0.02), ZGNX: 1.15 (-0.02), WGBS: 3.51 (-0.03), SPWH: 7.31 (-0.20)
Drugmaker submits harder-to-abuse Zohydro to FDA
By MATTHEW PERRONE - AP - Wed Oct 01, 1:33PM CDT
WASHINGTON (AP) — The maker of the much-debated painkiller Zohydro is seeking approval of a harder-to-abuse version of the drug which, if approved, could replace the currently marketed version of the pill by next spring.
ZGNX: 1.15 (-0.02)
Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for a modified formulation of Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII, which has been designed to have abuse deterrent properties. The new capsule formulation contains additional inactive ingredients that are intended to make the product more difficult to abuse by injection and nasal insufflation. The Company anticipates a target action date on the supplement during the first quarter of 2015, and, if approved, a transition from the currently marketed product to this new formulation of Zohydro ER in the second quarter of 2015.
ZGNX: 1.15 (-0.02)
